论文部分内容阅读
目的 :观察两种耐药基因谷胱甘肽S 转移酶 pi(GST π)和MDR1在卵巢癌组织中mRNA水平的表达情况 ,探讨其表达的意义及应用价值。方法 :采用逆转录PCR方法检测了 18例卵巢癌和10例正常卵巢组织中GST π和MDR1的表达 ,应用 β 肌动蛋白作为内对照进行定量分析比较。 结果 :GST π和MDR1在正常卵巢组织中表达的阳性率分别是 2 0 %和 10 % ,在卵巢癌中的阳性表达率分别是 6 1.1%和 33.3%。GST π在癌组织表达高于正常组织 ,两者比较P <0 .0 5;而MDR1在癌组织表达虽高于正常组织但无统计学意义 ;在癌组织中有 4例同时出现了GST π和MDR1的共表达 ;GST πmRNA水平的表达低于蛋白水平的表达。结论 :(1)GST π和MDR1在卵巢癌组织中的表达均高于正常卵巢组织 ,但以GST π为主 ;(2 )GST π和MDR1在癌组织中的表达不一致 ,说明两者的作用机制不同 ;而共表达现象的存在 ,又说明GST π和MDR1可能有相同的调节因素存在 ;(3)GST πmRNA水平的表达低于蛋白水平的表达 ,提示GST π表达还存在转录后加工和 (或 )翻译水平的调控。
Objective: To observe the expression of two drug resistance genes, glutathione S transferase pi (GST π) and MDR1 in ovarian cancer tissue, and to explore the significance and value of their expression. Methods: The expression of GST π and MDR1 in 18 cases of ovarian cancer and 10 cases of normal ovarian tissue were detected by RT-PCR. Β-actin was used as internal control for quantitative analysis and comparison. RESULTS: The positive rates of GST π and MDR1 expression in normal ovarian tissues were 20% and 10%, respectively. The positive rates of GST π and MDR1 in ovarian cancer were 61.1% and 33.3%, respectively. The expression of GST π was higher in cancerous tissues than in normal tissues, P <0.05; however, the expression of MDR1 in cancer tissues was higher than that in normal tissues, but there was no statistical significance in GST π And MDR1 co-expression; GST πmRNA level expression lower than the protein level expression. Conclusions: (1) The expression of GST π and MDR1 in ovarian cancer tissues is higher than that in normal ovarian tissues, but mainly in GST π. (2) The expression of GST π and MDR1 in cancer tissues is not consistent, indicating the role of both (3) The expression of GST πmRNA level is lower than the protein level, suggesting that GST π expression exists in the post-transcriptional processing and (3) the expression of GST π and MDR1 may exist the same regulatory factors; Or) translational regulation.